Eventide Asset Management, LLC Biomarin Pharmaceutical Inc Transaction History

Eventide Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $5.76 Million - $7.7 Million	-65,701 Reduced 28.57%	164,299 $16 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $18.6 Million - $25 Million	230,000 New	230,000 $23.8 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $10.6 Million - $14 Million	-132,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $5.35 Million - $6.03 Million	57,000 Added 76.0%	132,000 $12.8 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $6.05 Million - $7.12 Million	75,000	75,000 $6.98 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.